Bone Metastasis Market: Global Overview and Forecast (2022-2029)

Bone Metastasis Market Overview:

Bone Metastasis is cancer spread from the original (primary) tumor to the bone. Cancer cells break off from a primary tumor and target the bone with an extensive blood supply. Bones are a habitual place for these cancer cells to settle and start to proliferate. Once cancer has spread to bones, it’s rarely able to be cured. So, diagnosis based on signs, symptoms and imaging with new classes of drug treatment is leading to a better quality of life for patients and improved expectancy of life. The growing number of minimally invasive surgical procedures and increasing cases of cancer are the key factors responsible for driving the growth of the bone metastasis market.

 

Bone Metastasis Market Scope and Research Methodology:

The Bone Metastasis market report represents available treatment practices, new drugs along with personalized therapies for BM. In recent years there are many discoveries in the field of technologies with regard to the Bone Metastasis Market, which in turn will help the industry to grow. In- detailed analysis of competition, developing technologies, and strategies in the Bone Metastasis Market is covered in the report.

 

The financial standing, merger and acquisition and joint ventures are included in the competitive landscape for the Bone Metastasis market. The report includes primary and secondary data collection techniques which give detailed information about market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

 

Bone Metastasis Market Dynamics:

Drivers:

1. Growing Technological Advancements Penetrate the Bone Metastasis Market

Bone Metastasis market is driven by technological advancements for cancer treatment as there is an increase in the popularity of advanced personalized therapies like biological & targeted drug therapies and rise in the geriatric population across the world. Furthermore, government funding accelerated research and development to support cancer research. For example, in September 2022, the Head Control Committee of the CPRIT (Cancer Prevention and Research Institute of Texas) planned to approve around USD 49 million in new research grants. Additionally, new treatment development with clinical trials boosts several opportunities that witness lucrative growth in the bone metastatic market by 2029.

 

2. Increase In the Geriatric Population

Increasing number of bone metastasis due to the rise in cancer cases in the growing population following unhealthy lifestyles is one of the major factors driving revenue growth of the bone metastasis market. As a majority of newly diagnosed cancer cases is affecting adults aged 60 years and above. According to recent data published by WHO, 1 in 6 people will be aged 60 years or over, since age is a risk factor for cancer, the prevalence of bone metastasis is expected to rise globally.

 

Restraints:

1. High-Cost Treatment

As cancer treatment cost too much which is not affordable for those with an average income. A recent report by the US Bureau of Labour Statistics, states that the average monthly cost of cancer treatment is around $1000 - $12000 depending upon treatment type, which is literally 3 times to typical income of a patient. So, the high-cost treatment hinders the market growth by the forecast period.

 

2. Slow Approval Process by FDA

The growth of the Bone Metastasis market is hampered by strict government policies to approve novel treatments or drugs in use, and this fails to provide healthcare services to users. Additionally, the lack of good diagnostic services slows down the Bone metastasis market growth as undiagnosed Bone Metastasis in Solid Tumors cases and the absence of effective treatment are major obstructions to the bone metastasis industry.

 

Bone Metastasis Market Segment Analysis:

The Bone Metastasis market is segmented based on Type, Product, Origin, Diagnosis, Treatment, Age, End-users and region. The development of these segments will aid in the analysis of the industry's growth segments and give users a reliable market overview and market insights with market drivers and risks by 2029.

 

Based On Bone Metastasis Types: The Bone Metastasis market is segmented into Osteolytic Bone Metastasis, Osteoblastic Bone Metastasis and Mixed Bone Metastasis. Osteolytic Bone Metastasis is nothing but a breakdown of breast cancer cells and spread to bone through blood. While Osteoblastic Bone Metastasis is the process of invading the bone by primary cancer resulting in the formation of sclerosis. Among those Osteolytic Bone Metastasis lead the market share as it is directly linked to breast cancer, and the high prevalence of breast cancer (i.e., it accounts for 1 in 3 new female cancer annually) compared to other types of cancers is estimated to contribute the dominant share of the segment over the forecast period.

 

Based on Bone Metastasis Treatment: The Bone Metastasis market is segmented into Drug Treatment, Osteoplasty, Orthopedic Fixation, Medical Therapies, Surgical Treatment, Hormone Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, biopharmaceuticals and Medication.  Targeted Therapy attributes the market dominance because it interferes with specific proteins, focusing on specific molecular changes to design a personalized therapy. Additionally, Drug treatment and Chemotherapy share around 50% shares in the treatment segment which further leads to a rise in the market by 2029.

 

Based on Bone Metastasis Diagnosis: The Bone Metastasis market is segmented into Biopsy, Blood Test, and Imaging. Imaging holds the largest share in the diagnosis domain, as it has which is further sub-segmented into Radiography, computerized Tomography, MRI etc. Imaging has a significant role in the early discovery, diagnosis, and planning of the appropriate course of treatment for bone metastases, aiding to boost the market revenue throughout the forecast period.

Bone Metastasis Market Regional Insights:

North America is expected to dominate the bone metastasis industry by 2029 in terms of value, on account of the high incidence of prostate cancer. As per statistics from the American Cancer Society, approximately 268,490 new prostate cancer cases were expected to be diagnosed in the region. As well as developed healthcare sector, the increasing number of breast cancer with the presence of key players such as Merck & Co., Inc. and Pfizer Inc. within the Americas boosts the market growth.

 

Europe holds 2^nd rank in the bone metastasis market as it has the availability of funds for research and the presence of a huge patient population. Followed by Asia Pacific as the presence of evolving economies such as India and China along with the developing healthcare sector, drive the market growth in the region over the forecast period.

 

Competitive Landscape:  

The market for bone metastasis is extremely competitive and has a good number of key companies like Bayer AG, Merck & Co., Inc., Pfizer Inc., Novartis AG, Pharmalucence Inc., Koninklijke Philips N.V., GE Healthcare, Siemens, Amgen Inc, Catena Pharmaceuticals, Eli Lilly and Company, Roche. The market key players are either established providers of therapeutic modalities like chemotherapy and radiation therapy, or they are focusing on clinical trials for cutting-edge bone metastasis treatments like targeted therapy and immunotherapy. For eg., Novartis provides 4 bold approaches which focus on reimagining cancer care by targeted therapy, cell and gene therapy, radioligand therapy and Immune-oncology.

 

Additionally, advanced research in personalized medicine gives assurance in treatment procedures for bone metastasis market, Merck & Co. is developing cancer vaccines based on patients’ specific cancer that has the potential to boost the immune system to recognize certain characteristics and kill the cancerous cells.

 

The research also offers a detailed analysis of the Bone Metastasis market key players based on their earnings, offerings, market share, recent developments, mergers and acquisitions, and growth rates over the previous five years. Recently, Johnson & Johnson successfully acquired Momenta Pharmaceuticals Inc. in October 2020 to provide more upside potential for a wide range of disease conditions including infectious diseases, vaccines and oncology.

 

Bone Metastasis Market Scope:

 

Bone Metastasis Market Scope
Market Size in 2022	USD 15.90 Bn.
Market Size in 2029	USD 30.15 Bn.
CAGR (2023-2029)	8.4  Percent
Historic Data	2017-2021
Base Year	2022
Forecast Period	2023-2029
Segment Scope	By Type Osteolytic Bone Metastasis (Breast) Osteoblastic Bone Metastasis (Prostate) Mixed Bone Metastasis
	By Product Pain Relievers Bone Building medications Targeted Therapy Agents
	By Origin Breast Lung Thyroid Kidney Prostate Others
	By Diagnosis Biopsy Blood Test Imaging Others
	By Treatment Drug Treatment Osteoplasty Orthopedic Fixation Medical Therapies Surgical Treatment Medication Chemotherapy Hormone Therapy Targeted Therapy Immunotherapy Radiopharmaceuticals Others
	By Age Pediatrics Adults Geriatrics
Regional Scope	North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

 

 

 

Bone Metastasis Market, by region

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America

Bone Metastasis Market Key Players

• Bayer AG
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Pharmalucence Inc.
• Koninklijke Philips N.V.
• GE Healthcare
• Siemens
• Amgen Inc
• Catena Pharmaceuticals
• Eli Lilly and Company
• Roche,
• Fresenius Kabi
• Omega Laboratories
• Johnson and Johnson
• Advaxis, Inc,
• Takeda Pharmaceutical Company Limited,
• Cancervax, Inc,
• Cellectar Biosciences, Inc,
• Isofol Medical Ab,
• Gradalis Inc,
• Hikma Pharmaceutical PLC,
• QSAM Biosciences, Inc.,
• Zentalis Pharmaceuticals